How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Brain Tumor Treatm Market
- By Treatment Modality: Surgical Resection, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
- By Tumor Type: Glioblastoma Multiforme, Meningioma, Astrocytoma, Oligodendroglioma, Medulloblastoma
- By Drug Class: Alkylating Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Anti-angiogenic Agents
- By Radiation Therapy Technique: External Beam Radiation Therapy (EBRT), Stereotactic Radiosurgery (SRS), Proton Beam Therapy, Brachytherapy
- By Patient Age Group: Pediatric, Adult, Geriatric
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Resection leads By Treatment Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Brain Tumor Treatm Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Treatment Modality 5
Tumor Type 5
Drug Class 5
Radiation Therapy Technique 4
Patient Age Group 3
Companies profiled
Novocure
Eisai Co. Ltd.
Merck & Co. Inc.
Bristol-Myers Squibb Company
Roche Holding AG
Pfizer Inc.
AbbVie Inc.
Celgene Corporation (a Bristol-Myers Squibb company)
AstraZeneca plc
Genentech
Inc. (a member of the Roche Group)
InSightec Ltd.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novocure
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eisai Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Celgene Corporation (a Bristol-Myers Squibb company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Genentech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (a member of the Roche Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →InSightec Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Varian Medical Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Inc. (a Siemens Healthineers company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Elekta AB
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Medtronic plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Stryker Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,490M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Resection41.4
- Radiation Therapy9.6
- Chemotherapy14.9
- Targeted Therapy12.1
- Immunotherapy21.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,186M → $1,777M · 5.2%
Europe$826.7M → $1,308M · 5.9%
Asia Pacific$754.8M → $1,177M · 5.7%
Latin America$467.3M → $771.5M · 6.5%
Middle East and Africa$359.4M → $508.5M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.382026
5.392027
5.422028
5.422029
5.442030
5.452031
5.472032
5.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novocure12.8
- Eisai Co. Ltd.13.4
- Merck & Co. Inc.12.1
- Bristol-Myers Squibb Company8.4
- Roche Holding AG12.1
- Pfizer Inc.13.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Modality28.2%
Tumor Type27.3%
Drug Class15.5%
Radiation Therapy Technique18.7%
Patient Age Group10.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe23.6
- Asia Pacific21.2
- Latin America13.9
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novocure | 88 | 92 | 91 | 95 | 83 | 85 | 89 |
| Eisai Co. Ltd. | 81 | 89 | 70 | 76 | 69 | 88 | 79 |
| Merck & Co. Inc. | 83 | 72 | 78 | 78 | 64 | 67 | 74 |
| Bristol-Myers Squibb Company | 73 | 82 | 66 | 74 | 75 | 69 | 73 |
| Roche Holding AG | 65 | 52 | 64 | 71 | 54 | 73 | 63 |
| Pfizer Inc. | 51 | 50 | 54 | 60 | 69 | 47 | 55 |
| AbbVie Inc. | 54 | 66 | 53 | 45 | 45 | 57 | 53 |
| Celgene Corporation (a Bristol-Myers Squibb company) | 57 | 48 | 54 | 56 | 56 | 41 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novocure
- Eisai Co. Ltd.
- Merck & Co. Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novocure | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Eisai Co. Ltd. | ◐ | ◐ | ✓ | ✓ | − | ✓ |
| Merck & Co. Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Bristol-Myers Squibb Company | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| Roche Holding AG | ◐ | − | ✓ | − | ◐ | ✓ |
| Pfizer Inc. | − | ◐ | − | − | ✓ | − |
| AbbVie Inc. | − | ◐ | − | − | ◐ | ◐ |
| Celgene Corporation (a Bristol-Myers Squibb company) | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novocure89
2Eisai Co. Ltd.79
3Merck & Co. Inc.74
4Bristol-Myers Squibb Company73
5Roche Holding AG63
6Pfizer Inc.55
7AbbVie Inc.53
8Celgene Corporation (a Bristol-Myers Squibb company)52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
NovocureEisai Co. Ltd.
Challenger2
Strong scale, closing on the leaders.
Merck & Co. Inc.Bristol-Myers Squibb Company
Contender1
Focused players with pockets of strength.
Roche Holding AG
Niche3
Specialists in a single segment or region.
Pfizer Inc.AbbVie Inc.Celgene Corporation (a Bristol-Myers Squibb company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Modality in North America, then scale across Brain Tumor Treatm Market — a $93M beachhead inside a $1.48B market.
Beachhead (SOM)$93Mobtainable near-term
Serviceable (SAM)$595Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Surgical Resection
Best fit — highest urgency & budget in Treatment Modality.
Economic buyer78 fit
Radiation Therapy
Strong fit — clear ROI and a fast path to value.
End user67 fit
Chemotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tumor Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Brain Tumor Treatm Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified26%
Evaluation15%
Closed-won6%
$21.9KCAC
$86KLTV
3.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Brain Tumor Treatm Market is a resilient opportunity — $7.20B by 2033, compounding at 5.0%.
TAM · 2025$4.88Btoday
TAM · 2033$7.20Bforecast
CAGR5.0%2027–2033
Cumulative$53.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.20BTotal addressable market
SAM$2.67BServiceable available market
SOM$537MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.0% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Modality moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.20BLarge & growingTAM by 2033 at 5.0% CAGR
$2.67BServiceable nowreachable with today’s model
$537MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.61BBear3.2% CAGR
$7.20BBase5.0% CAGR
$9.21BBull6.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tumor Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Brain Tumor Treatm Market — a $3.90B market by 2033. Plan: grow share from 5.9% to 12.9%.
Market size · 2033$3.90Btotal addressable
Market CAGR4.6%2027–2033
Target share12.9%from 5.9% today
Revenue ambition$503Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.9% | 12.9% | Ahead |
| Revenue | $246M | $503M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 28.9% | 42.4% | On track |
| Customer retention | 89.0% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tumor Type capability
A defensible second engine — invest in Tumor Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tumor Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $67M capacity & capability investment
- Greenlight bolt-on M&A in Tumor Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Brain Tumor Treatm Market conversation — a $3.14B market you can size, segment and defend in minutes.
Market size · 2033$3.14Btotal opportunity
Growth7.0%CAGR to 2033
Addressable buyers1,143+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Modality
Goal Grow share in Treatment Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
NovocureEisai Co. Ltd.Merck & Co. Inc.Bristol-Myers Squibb CompanyRoche Holding AGPfizer Inc.AbbVie Inc.Celgene Corporation (a Bristol-Myers Squibb company)+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Brain Tumor Treatm Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Brain Tumor Treatm Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Brain-Computer Interface Hand Rehabilitation Robot Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBrain-like computing chips Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBrainwave Synchronization Therapy Device Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBrake Adjustment Arm Market
Market size, share, segmentation and regional forecast.
$952M market · 2025 base year
View reportBrake Booster Pump Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBrake Branch Pump Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBrake Branch Pump Repair Kits Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBrake Components Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBrake Control System Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportBrake Control Systems Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBrake Cooling Oil Chamber Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportBrake Cooling Oil Pump Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.